NCT00033891View on ClinicalTrials.gov

Infliximab (Remicade ) to Treat Dermatomyositis and Polymyositis

PHASE2CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

April 10, 2002

Primary Completion Date

July 31, 2007

Study Completion Date

May 20, 2010

Conditions
DermatomyositisPolymyositis
Interventions
DRUG

Infliximab

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

NIH

NCT00033891 - Infliximab (Remicade ) to Treat Dermatomyositis and Polymyositis | Biotech Hunter | Biotech Hunter